Individuals with neurofibromatosis type 1(NF1) carry mutations in the NF1 tumor suppressor and develop benign peripheral nerve sheath tumors called neurofibromas. Neurofibromas contain normal nerve constituents: axons, Schwann cells, fibroblasts, and mast cells, as well as increased numbers of mast cells, excessive collagen, and Schwann cells free of axons. Tumorigenesis results from complete loss of function at NF1, as neurofibromas are characterized by biallelic mutations in tumor Schwann cells. Other cell types may be recruited secondarily. We developed a mouse model system for Schwann cell tumorigenesis in NF1, and identified aberrant expression of epidermal growth factor receptor in Nflthis model. EGFR also shows increased expression in human tumor samples. We expressed EGFR in transgenic mouse Schwann cells reproducing early phases of neurofibroma formation in mice including Schwann cell migration from axons, attraction of mast cells to peripheral nerve, and fibrosis. These models provide unique opportunities to study early events in peripheral nerve tumorigenesis. In this application we propose to use cell culture systems to test when in development EGFR expression generates a tumorigenic cell, and to characterize a human EGFR- expressing Schwann cell within neurofibromas. Finally, we will define cellular changes secondary to EGFR expression in the new transgenic model, focusing on the effects of mast cell recruitment. Together, these studies will identify cellular and molecular underpinnings of tumor formation in the nervous system, and identify therapeutic targets for the treatment of NF1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS028840-20
Application #
7759220
Study Section
Neurogenesis and Cell Fate Study Section (NCF)
Program Officer
Fountain, Jane W
Project Start
1990-08-01
Project End
2011-09-14
Budget Start
2010-02-01
Budget End
2011-09-14
Support Year
20
Fiscal Year
2010
Total Cost
$425,581
Indirect Cost
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Wu, J; Liu, W; Williams, J P et al. (2017) EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation. Oncogene 36:1669-1677
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
Ratner, Nancy; Brodeur, Garrett M; Dale, Russell C et al. (2016) The ""neuro"" of neuroblastoma: Neuroblastoma as a neurodevelopmental disorder. Ann Neurol 80:13-23
Wu, Jianqiang; Keng, Vincent W; Patmore, Deanna M et al. (2016) Insertional Mutagenesis Identifies a STAT3/Arid1b/?-catenin Pathway Driving Neurofibroma Initiation. Cell Rep 14:1979-90
Kendall, Jed J; Chaney, Katherine E; Patel, Ami V et al. (2016) CK2 blockade causes MPNST cell apoptosis and promotes degradation of ?-catenin. Oncotarget 7:53191-53203
Li, H; Zhao, X; Yan, X et al. (2016) Runx1 contributes to neurofibromatosis type 1 neurofibroma formation. Oncogene 35:1468-74
Ratner, Nancy; Miller, Shyra J (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15:290-301
Wu, J; Patmore, D M; Jousma, E et al. (2014) EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors. Oncogene 33:173-80
Brundage, M E; Tandon, P; Eaves, D W et al. (2014) MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene 33:5626-36
Jessen, Walter J; Miller, Shyra J; Jousma, Edwin et al. (2013) MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 123:340-7

Showing the most recent 10 out of 55 publications